712 North Inc. Establishes New Laboratory at the QB3 Garage at UC Berkeley

July 1, 2019 — 712 North Inc., a discovery-stage therapeutics company specializing in mitochondrial medicine, announced today that it has joined the QB3 Garage at UC Berkeley. QB3 (the California Institute for Quantitative Biosciences) is a premier life science incubator created by the University of California to foster innovation and support high-growth entrepreneurship.

The move provides 712 North with dedicated laboratory space advance the development of personalized mitochondrial medicines for Alzheimer’s and other age-related diseases.

"Our new lab on the UC Berkeley campus is great," said Dr. Marcel V. Alavi, CEO of 712 North. "The QB3 Garage offers a world-class environment for discovery-stage companies. Being embedded in this community provides us with unique access to potential partners and collaborators."

The company’s operations are currently supported by a Small Business Innovation Research (SBIR) grant awarded by the National Institute on Aging (NIA). This funding facilitates the early-stage development of therapeutic platforms targeting mitochondrial quality control and protease activity.

712 North develops personalized mitochondrial medicines for patients with Alzheimer’s and other age-related diseases.

For more information, please visit www.712north.com.